21 U.S.C. § 379j–52 — Authority to assess and use biosimilar biological product fees
submitted 88 years ago by Pub. L. 112-144 to r/title-21-FOOD-AND-DRUGS · 4,944 words · no verdicts yet
This section lets the FDA charge biosimilar drug makers three kinds of fees. It sets how much each fee raises and adjusts amounts yearly for inflation, staffing, and reserves. It also covers small business waivers, unpaid fees, and how the FDA may spend the money.
(a) Types of fees. Starting in fiscal year 2023, the Secretary* must charge three kinds of fees.
(1) Biosimilar biological product development program* fees. (A) Initial fee: anyone who requests a biosimilar development meeting, or who files a clinical trial protocol under an investigational new drug* (IND) application that the Secretary decides is meant to support a biosimilar application, must pay an initial development fee for that product. It is due by the earlier of 7 days after the FDA grants the meeting request, or the date the IND application is filed. Anyone who had already filed an IND before July 9, 2012 must pay this fee by the earlier of 60 days after July 9, 2012 (if the FDA decides that IND supports a biosimilar application) or 7 days after the FDA grants a meeting request.
(B) Annual fee: anyone who paid the initial fee for a product must then pay an annual fee starting the next fiscal year, unless the product (and its IND, where relevant) has been transferred to a new owner — in which case the new owner pays instead, once the FDA has written notice of the transfer. The annual fee is due on the later of the first business day on or after October 1, or the first business day after that year's appropriations act is enacted. It is not due if the person* has filed a marketing application that was accepted for filing, has dropped out of the development program for the product, or has been administratively removed from the program. Anyone who files a marketing application before October 1 that is later accepted for filing may ask for a refund of that year's annual fee, but must submit the written refund request within 180 days after the application is accepted.
(C) Dropping out: a person may quit the development program for a product, effective the next October 1, by notifying the Secretary in writing by the prior August 1 — either declaring they don't intend to keep developing the product (if no IND was filed), or formally withdrawing the IND (if one was filed).
(D) Reactivation fee: anyone who dropped out or was administratively removed and wants back in must pay all owed past annual fees plus a reactivation fee, by the earlier of 7 days after the FDA grants a new meeting request or the date a new IND is filed for the product. After paying it, they go back to owing the regular annual fee starting the next year (again shifting to a new owner with written notice of a transfer).
(E) Consequences of nonpayment: if required fees under (A), (B), or (D) go unpaid, the FDA will not hold a development meeting for that product; will not, except in extraordinary circumstances, treat an IND as received for that product; must, except in extraordinary circumstances, put the clinical trial on a "financial hold*"; will treat any application or supplement* from that person as incomplete and refuse to accept it for filing until all owed fees are paid; and, if annual fees go unpaid for two straight fiscal years, may administratively remove the person from the program — but only after giving 30 days' written notice first.
(F) Limits: fees paid under (A) or (B), and reactivation fees under (D), cannot be refunded except for the marketing-application refund in (B). The FDA also may not waive, exempt, or reduce these fees.
(2) Biosimilar biological product application* fee. (A) Starting October 1, 2017, anyone filing a biosimilar application owes a full fee if clinical safety or effectiveness data (other than bioavailability comparison studies) are required for approval, or half that fee if such clinical data are not required. (B) Anyone who already paid a development-program fee for a product before October 1, 2017 but files the application after that date still owes the full application fee, with no credit for fees paid earlier. (C) The application fee is due when the application is submitted. (D) If someone already paid the application fee once, the application was accepted for filing, and it was never approved or was withdrawn before approval without a waiver, then a later application for the same product by the same person or their successor does not owe the fee again. (E) If an application is refused for filing or withdrawn before filing, the FDA must refund 75 percent of the fee paid. (F) An application that was refused for filing, or withdrawn before being accepted or refused, owes the full fee again if resubmitted or filed over protest, unless a waiver applies under subsection (d).
(3) Biosimilar biological product* program fee. (A) Anyone named as the applicant on an approved biosimilar application owes an annual program fee for each biosimilar product that is listed in an application approved as of October 1 of that year, can only be dispensed by prescription, and is not on the FDA's list of discontinued biosimilar products as of that October 1. (B) It is due on the later of the first business day on or after October 1, or the first business day after that year's appropriations act is enacted. (C) It is paid only once per product per year. (D) No applicant owes more than 5 program fees in a year, however many products they have. (E) A product counts as moved to the discontinued list as of the later of when the FDA received a written request saying so, or a future withdrawal date given in that request; a product counts as withdrawn from sale once the applicant stops distributing it itself, even without recalling old stock, except that a routine, temporary supply interruption does not count as a withdrawal. If a product is on the discontinued list as of October 1 but comes off that list later in the same fiscal year, the applicant still owes the full annual program fee for it, due that time on the last business day of the fiscal year, and still only once per product per year.
(b) Fee revenue amounts. For fiscal years 2023 through 2027, the total amount the fees under (a) must raise equals the sum of: the year's base revenue (set under (b)(3)); an inflation adjustment (under (c)(1)); a strategic hiring and retention adjustment (under (c)(2)); a capacity planning adjustment (under (c)(3)); an operating reserve adjustment if one applies (under (c)(4)); plus, only for fiscal year 2023, an extra $4,428,886; and only for fiscal year 2024, an extra $320,569. The Secretary decides what share of that total comes from each of the three fee types. The initial development fee must equal that year's annual development fee. The reactivation fee must equal twice that year's annual development fee. The annual base revenue is $43,376,922 for fiscal year 2023; for 2024 through 2027 it equals the prior year's total revenue amount, not counting any operating-reserve adjustment.
(c) Adjustments; annual fee setting. (1) The inflation adjustment equals the base revenue times an inflation percentage, which is the sum of: the average yearly percent change in per-employee FDA personnel pay and benefits over the first three of the preceding four fiscal years, times the share of total review costs coming from personnel pay and benefits; plus the average yearly percent change in the Washington-area urban Consumer Price Index over that same three-year window, times the share of total review costs that are not personnel pay and benefits. (2) After applying the inflation adjustment, the Secretary must add a flat $150,000 to the fee revenue each year. (3) Each year, on top of (1) and (2), the Secretary must further adjust fees to reflect the FDA's changing resource needs, using the same forecasting method used for fiscal year 2021 fees, described in an August 4, 2020 Federal Register notice. The forecast may count only the workload categories used in that 2021 notice, plus, where practical, closely related new activities such as additional formal meeting types and direct review of postmarketing commitments, risk evaluation and mitigation strategies, and annual reports — it may not count other activities, including ones the FDA mentioned as possible future uses in 2021 but did not actually use. This adjustment can never push total fee revenue below the sum of the base revenue, inflation adjustment, and hiring and retention adjustment. The resulting fees and the method used must be published in the Federal Register. (4) Starting in fiscal year 2023, the Secretary must raise fees further if needed to keep at least 10 weeks of carryover reserve funds on hand. The Secretary must lower fees if carryover reserves exceed a cap: above 33 weeks for 2023, above 27 weeks for 2024, and above 21 weeks for 2025 and later, reducing fees enough to bring reserves back within that cap. Any such increase or decrease, and the reason for it, must be explained in the year's Federal Register notice. (5) At least 60 days before each fiscal year starting with 2023, the Secretary must set that year's development, application, and program fees based on the revenue targets and adjustments above, and publish them in the Federal Register. (6) Total fees for a year can never exceed the FDA's total costs that year for reviewing biosimilar applications.
(d) Application fee waiver for small business. (1) The FDA must waive the application fee under (a)(2)(A) for a small business's, or its affiliate's, very first biosimilar application; every application after that first one is charged normally. (2) In deciding whether to grant the waiver, the FDA may consider only the finances of the applicant and its affiliates. (3) "Small business" means a company with fewer than 500 employees, counting affiliates' employees, that has never had a drug* approved and put into interstate commerce* under either a human drug application or a biosimilar application.
(e) Effect of failure to pay fees. Any biosimilar application or supplement from someone who owes fees under (a) is treated as incomplete and will not be accepted for filing until all owed fees are paid.
(f) Crediting and availability of fees. (1) Fees may be spent only to the extent Congress provides for it in appropriations acts, though unspent fees stay available until spent. Money may be shifted between the FDA's general salaries account and the fee-funded account, but the transferred amount may only be used for reviewing biosimilar applications. (2) Fees may be collected and spent each year only up to the amount set in that year's appropriations act. For fiscal year 2023, the fees may be used only if the FDA also spends at least $20 million, adjusted by the "adjustment factor," from non-fee sources on this review process; for 2024 and later years, that same inflation-adjusted $20 million floor applies to combined non-fee spending on the review process plus related facility and equipment costs. Starting October 1, 2023, the facilities category in the "costs of resources" definition covers only leasing and necessary scientific equipment. The FDA is considered to have met this non-fee spending requirement even if actual spending is up to 15 percent below the required level. The FDA may accept fee payments early, ahead of the normal due date, if a prior year's appropriations act allows it. (3) For fiscal years 2023 through 2027, Congress is authorized to appropriate an amount equal to whatever fees are actually assessed that year.
(g) Collection of unpaid fees. If a fee is not paid within 30 days of its due date, it is treated as a debt owed to the United States government under the federal debt-collection law in subchapter II of chapter 37 of title 31.
(h) Written requests for waivers and returns; disputes concerning fees. To ask for a waiver under (d), or to get a fee returned — including a fee claimed to have been paid by mistake — a person must submit a written request explaining why, generally no later than 180 days after the fee was due, citing the legal basis for the request.
(i) Construction. Nothing in this section requires the Department* of Health and Human Services to cut staff or advisory-committee positions not involved in reviewing biosimilar applications, just to offset the staff hired for that review process.
Beginning in fiscal year 2023, the Secretary* shall assess and collect fees in accordance with this section as follows:
Each person* that submits to the Secretary a meeting request described under clause (ii) or a clinical protocol for an investigational new drug* protocol described under clause (iii) shall pay for the product named in the meeting request or the investigational new drug* application the initial biosimilar biological product development fee established under subsection (c)(5).
The meeting request described in this clause is a request for a biosimilar biological product development meeting* for a product.
A clinical protocol for an investigational new drug protocol described in this clause is a clinical protocol consistent with the provisions of section 355(i) of this title, including any regulations promulgated under section 355(i) of this title, (referred to in this section as “investigational new drug application”) describing an investigation that the Secretary determines is intended to support a biosimilar biological product application* for a product.
The initial biosimilar biological product development fee shall be due by the earlier of the following:
Not later than 7 days after the Secretary grants a request for a biosimilar biological product development meeting.
The date of submission of an investigational new drug application describing an investigation that the Secretary determines is intended to support a biosimilar biological product application.
Each person that has submitted an investigational new drug application prior to July 9, 2012, shall pay the initial biosimilar biological product development fee by the earlier of the following:
Not later than 60 days after July 9, 2012, if the Secretary determines that the investigational new drug application describes an investigation that is intended to support a biosimilar biological product application.
Not later than 7 days after the Secretary grants a request for a biosimilar biological product development meeting.
A person that pays an initial biosimilar biological product development fee for a product shall pay for such product, beginning in the fiscal year following the fiscal year in which the initial biosimilar biological product development fee was paid, an annual fee established under subsection (c)(5) for the biosimilar biological product development program (referred to in this section as “annual biosimilar biological product development fee”), except that, in the case that such product (including, where applicable, ownership of the relevant investigational new drug application) is transferred to a licensee, assignee, or successor of such person, and written notice of such transfer is provided to the Secretary, such licensee, assignee, or successor shall pay the annual biosimilar biological product development fee.
The annual biosimilar biological product development fee for each fiscal year will be due on the later of—
the first business day on or after October 1 of each such year; or
the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.
The annual biosimilar biological product development fee for each fiscal year will be due on the date specified in clause (ii), unless the person has—
submitted a marketing application for the biological product that was accepted for filing;
discontinued participation in the biosimilar biological product development program for the product under subparagraph (C); or
been administratively removed from the biosimilar biological product development program for the product under subparagraph (E)(v).
If a person submits a marketing application for a biosimilar biological product before October 1 of a fiscal year and such application is subsequently accepted for filing, the person may request a refund equal to the annual biosimilar biological product development fee paid by the person for the product for such fiscal year. To qualify for consideration for a refund under this clause, a person shall submit to the Secretary a written request for such refund not later than 180 days after the marketing application is accepted for filing.
A person may discontinue participation in the biosimilar biological product development program for a product, effective October 1 of a fiscal year, by, not later than August 1 of the preceding fiscal year—
if no investigational new drug application concerning the product has been submitted, submitting to the Secretary a written declaration that the person has no present intention of further developing the product as a biosimilar biological product; or
if an investigational new drug application concerning the product has been submitted, withdrawing the investigational new drug application in accordance with part 312 of title 21, Code of Federal Regulations (or any successor regulations).
A person that has discontinued participation in the biosimilar biological product development program for a product under subparagraph (C), or who has been administratively removed from such program for a product under subparagraph (E)(v), shall, if the person seeks to resume participation in such program, pay all annual biosimilar biological product development fees previously assessed for such product and still owed and a fee (referred to in this section as “reactivation fee”) by the earlier of the following:
Not later than 7 days after the Secretary grants a request by such person for a biosimilar biological product development meeting for the product (after the date on which such participation was discontinued or the date of administrative removal, as applicable).
Upon the date of submission (after the date on which such participation was discontinued or the date of administrative removal, as applicable) by such person of an investigational new drug application describing an investigation that the Secretary determines is intended to support a biosimilar biological product application for that product.
A person that pays a reactivation fee for a product shall pay for such product, beginning in the next fiscal year, the annual biosimilar biological product development fee under subparagraph (B), except that, in the case that such product (including, where applicable, ownership of the relevant investigational new drug application) is transferred to a licensee, assignee, or successor of such person, and written notice of such transfer is provided to the Secretary, such licensee, assignee, or successor shall pay the annual biosimilar biological product development fee.
If a person has failed to pay an initial or annual biosimilar biological product development fee as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D), the Secretary shall not provide a biosimilar biological product development meeting relating to the product for which fees are owed.
Except in extraordinary circumstances, the Secretary shall not consider an investigational new drug application to have been received under section 355(i)(2) of this title if—
the Secretary determines that the investigation is intended to support a biosimilar biological product application; and
the sponsor has failed to pay an initial or annual biosimilar biological product development fee for the product as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D).
Notwithstanding section 355(i)(2) of this title, except in extraordinary circumstances, the Secretary shall prohibit the sponsor of a clinical investigation from continuing the investigation if—
the Secretary determines that the investigation is intended to support a biosimilar biological product application; and
the sponsor has failed to pay an initial or annual biosimilar biological product development fee for the product as required under subparagraph (A) or (B), or a reactivation fee for the product as required under subparagraph (D).
If a person has failed to pay an initial or annual biosimilar biological product development fee as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D), any biosimilar biological product application or supplement* submitted by that person shall be considered incomplete and shall not be accepted for filing by the Secretary until all such fees owed by such person have been paid.
If a person has failed to pay an annual biosimilar biological product development fee for a product as required under subparagraph (B) for a period of 2 consecutive fiscal years, the Secretary may administratively remove such person from the biosimilar biological product development program for the product. At least 30 days prior to administratively removing a person from the biosimilar biological product development program for a product under this clause, the Secretary shall provide written notice to such person of the intended administrative removal.
Except as provided in subparagraph (B)(iv), the Secretary shall not refund any initial or annual biosimilar biological product development fee paid under subparagraph (A) or (B), or any reactivation fee paid under subparagraph (D).
The Secretary shall not grant a waiver, exemption, or reduction of any initial or annual biosimilar biological product development fee due or payable under subparagraph (A) or (B), or any reactivation fee due or payable under subparagraph (D).
Each person that submits, on or after October 1, 2017, a biosimilar biological product application shall be subject to the following fees:
A fee established under subsection (c)(5) for a biosimilar biological product application for which clinical data (other than comparative bioavailability studies) with respect to safety or effectiveness are required for approval.
A fee established under subsection (c)(5) for a biosimilar biological product application for which clinical data (other than comparative bioavailability studies) with respect to safety or effectiveness are not required for approval. Such fee shall be equal to half of the amount of the fee described in clause (i).
Any person who pays a fee under subparagraph (A), (B), or (D) of paragraph (1) for a product before October 1, 2017, but submits a biosimilar biological product application for that product after such date, shall—
be subject to any biosimilar biological product application fees that may be assessed at the time when such biosimilar biological product application is submitted; and
be entitled to no reduction of such application fees based on the amount of fees paid for that product before October 1, 2017, under such subparagraph (A), (B), or (D).
Any fee required by subparagraph (A) shall be due upon submission of the application for which such fee applies.
If a biosimilar biological product application was submitted by a person that paid the fee for such application, was accepted for filing, and was not approved or was withdrawn prior to approval (without a waiver), the submission of a biosimilar biological product application for the same product by the same person (or the person’s licensee, assignee, or successor) shall not be subject to a fee under subparagraph (A).
The Secretary shall refund 75 percent of the fee paid under this paragraph for any application which is refused for filing or withdrawn without a waiver before filing.
A biosimilar biological product application that was submitted but was refused for filing, or was withdrawn before being accepted or refused for filing, shall be subject to the full fee under subparagraph (A) upon being resubmitted or filed over protest, unless the fee is waived under subsection (d).
Each person who is named as the applicant in a biosimilar biological product application shall pay the annual biosimilar biological product program fee established for a fiscal year under subsection (c)(5) for each biosimilar biological product that—
is identified in such a biosimilar biological product application approved as of October 1 of such fiscal year;
may be dispensed only under prescription pursuant to section 353(b) of this title; and
as of October 1 of such fiscal year, does not appear on a list, developed and maintained by the Secretary, of discontinued biosimilar biological products.
The biosimilar biological product program fee for a fiscal year shall be due on the later of—
the first business day on or after October 1 of each such year; or
the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.
The biosimilar biological product program fee shall be paid only once for each product for each fiscal year.
A person who is named as the applicant in a biosimilar biological product application shall not be assessed more than 5 biosimilar biological product program fees for a fiscal year for biosimilar biological products identified in such biosimilar biological product application.
If a written request to place a product on the list referenced in subparagraph (A) of discontinued biosimilar biological products is submitted to the Secretary on behalf of an applicant, and the request identifies the date the product is, or will be, withdrawn from sale, then for purposes of assessing the biosimilar biological product program fee, the Secretary shall consider such product to have been included on such list on the later of—
the date such request was received; or
if the product will be withdrawn from sale on a future date, such future date when the product is withdrawn from sale.
For purposes of clause (i), a product shall be considered withdrawn from sale once the applicant has ceased its own distribution of the product, whether or not the applicant has ordered recall of all previously distributed lots of the product, except that a routine, temporary interruption in supply shall not render a product withdrawn from sale.
If a biosimilar biological product that is identified in a biosimilar biological product application approved as of October 1 of a fiscal year appears, as of October 1 of such fiscal year, on the list referenced in subparagraph (A) of discontinued biosimilar biological products, and on any subsequent day during such fiscal year the biosimilar biological product does not appear on such list, except as provided in subparagraph (D), each person who is named as the applicant in a biosimilar biological product application with respect to such product shall pay the annual biosimilar biological product program fee established for a fiscal year under subsection (c)(5) for such biosimilar biological product. Notwithstanding subparagraph (B), such fee shall be due on the last business day of such fiscal year and shall be paid only once for each such product for each fiscal year.
For each of the fiscal years 2023 through 2027, fees under subsection (a) shall, except as provided in subsection (c), be established to generate a total revenue amount equal to the sum of—
the annual base revenue for the fiscal year (as determined under paragraph (3));
the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));
the dollar amount equal to the strategic hiring and retention adjustment (as determined under subsection (c)(2));
the dollar amount equal to the capacity planning adjustment for the fiscal year (as determined under subsection (c)(3));
the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(4));
for fiscal year 2023 an additional amount of $4,428,886; and
for fiscal year 2024 an additional amount of $320,569.
The Secretary shall determine the percentage of the total revenue amount for a fiscal year to be derived from, respectively—
initial and annual biosimilar biological product development fees and reactivation fees under subsection (a)(1);
biosimilar biological product application fees under subsection (a)(2); and
biosimilar biological product program fees under subsection (a)(3).
The initial biosimilar biological product development fee under subsection (a)(1)(A) for a fiscal year shall be equal to the annual biosimilar biological product development fee under subsection (a)(1)(B) for that fiscal year.
The reactivation fee under subsection (a)(1)(D) for a fiscal year shall be equal to twice the amount of the annual biosimilar biological product development fee under subsection (a)(1)(B) for that fiscal year.
For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—
for fiscal year 2023, $43,376,922; and
for fiscal years 2024 through 2027, the dollar amount of the total revenue amount established under paragraph (1) for the previous fiscal year, excluding any adjustments to such revenue amount under subsection (c)(4).
For purposes of subsection (b)(1)(B), the dollar amount of the inflation adjustment to the annual base revenue for each fiscal year shall be equal to the product of—
such annual base revenue for the fiscal year under subsection (b)(1)(A); and
the inflation adjustment percentage under subparagraph (B).
The inflation adjustment percentage under this subparagraph for a fiscal year is equal to the sum of—
the average annual percent change in the cost, per full-time equivalent position of the Food* and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of the process for the review of biosimilar biological product applications* (as defined in section 379j–51(13) of this title) for the first 3 years of the preceding 4 fiscal years; and
the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Arlington-Alexandria, DC–VA–MD–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of the process for the review of biosimilar biological product applications (as defined in section 379j–51(13) of this title) for the first 3 years of the preceding 4 fiscal years.
For each fiscal year, after the annual base revenue under subsection (b)(1)(A) is adjusted for inflation in accordance with paragraph (1), the Secretary shall further increase the fee revenue and fees by $150,000.
For each fiscal year, the Secretary shall, in addition to the adjustments under paragraphs (1) and (2), further adjust the fee revenue and fees under this section for a fiscal year to reflect changes in the resource capacity needs of the Secretary for the process for the review of biosimilar biological product applications.
For purposes of this paragraph, the Secretary shall employ the capacity planning methodology utilized by the Secretary in setting fees for fiscal year 2021, as described in the notice titled “Biosimilar User Fee Rates for Fiscal Year 2021” published in the Federal Register on August 4, 2020 (85 Fed. Reg. 47220). The workload categories used in applying such methodology in forecasting shall include only the activities described in that notice and, as feasible, additional activities that are directly related to the direct review of biosimilar biological product applications and supplements, including additional formal meeting types, the direct review of postmarketing commitments and requirements, the direct review of risk evaluation and mitigation strategies, and the direct review of annual reports for approved biosimilar biological products. Subject to the exceptions in the preceding sentence, the Secretary shall not include as workload categories in applying such methodology in forecasting any non-core review activities, including those activities that the Secretary referenced for potential future use in such notice but did not utilize in setting fees for fiscal year 2021.
Under no circumstances shall an adjustment under this paragraph result in fee revenue for a fiscal year that is less than the sum of the amounts under subsections (b)(1)(A) (the annual base revenue for the fiscal year), (b)(1)(B) (the dollar amount of the inflation adjustment for the fiscal year), and (b)(1)(C) (the dollar amount of the strategic hiring and retention adjustment).
The Secretary shall publish in the Federal Register notice under paragraph (5) the fee revenue and fees resulting from the adjustment and the methodologies under this paragraph.
For fiscal year 2023 and subsequent fiscal years, the Secretary shall, in addition to adjustments under paragraphs (1), (2), and (3), further increase the fee revenue and fees if such an adjustment is necessary to provide for at least 10 weeks of operating reserves of carryover user fees for the process for the review of biosimilar biological product applications.
For fiscal year 2023, if the Secretary has carryover balances for such process in excess of 33 weeks of such operating reserves, the Secretary shall decrease such fee revenue and fees to provide for not more than 33 weeks of such operating reserves.
For fiscal year 2024, if the Secretary has carryover balances for such process in excess of 27 weeks of such operating reserves, the Secretary shall decrease such fee revenue and fees to provide for not more than 27 weeks of such operating reserves.
For fiscal year 2025 and subsequent fiscal years, if the Secretary has carryover balances for such process in excess of 21 weeks of such operating reserves, the Secretary shall decrease such fee revenue and fees to provide for not more than 21 weeks of such operating reserves.
If an adjustment under subparagraph (A) or (B) is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5)(B) establishing fee revenue and fees for the fiscal year involved.
For fiscal year 2023 and each subsequent fiscal year, the Secretary shall, not later than 60 days before the start of each such fiscal year—
establish, for the fiscal year, initial and annual biosimilar biological product development fees and reactivation fees under subsection (a)(1), biosimilar biological product application fees under subsection (a)(2), and biosimilar biological product program fees under subsection (a)(3), based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and
publish such fee revenue and fees in the Federal Register.
The total amount of fees assessed for a fiscal year under this section may not exceed the total costs for such fiscal year for the resources allocated for the process for the review of biosimilar biological product applications.
The Secretary shall grant to a person who is named in a biosimilar biological product application a waiver from the application fee assessed to that person under subsection (a)(2)(A) for the first biosimilar biological product application that a small business or its affiliate* submits to the Secretary for review. After a small business or its affiliate is granted such a waiver, the small business or its affiliate shall pay application fees for all subsequent biosimilar biological product applications submitted to the Secretary for review in the same manner as an entity that is not a small business.
In determining whether to grant a waiver of a fee under paragraph (1), the Secretary shall consider only the circumstances and assets of the applicant involved and any affiliate of the applicant.
In this subsection, the term “small business” means an entity that has fewer than 500 employees, including employees of affiliates, and does not have a drug product* that has been approved under a human drug application (as defined in section 379g of this title) or a biosimilar biological product application (as defined in section 379j–51(4) of this title) and introduced or delivered for introduction into interstate commerce*.
A biosimilar biological product application or supplement submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for filing by the Secretary until all such fees owed by such person have been paid.
Subject to paragraph (2), fees authorized under subsection (a) shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation to such appropriation account for salaries and expenses with such fiscal year limitation. The sums transferred shall be available solely for the process for the review of biosimilar biological product applications.
Subject to subparagraphs (C) and (D), the fees authorized by this section shall be collected and available in each fiscal year in an amount not to exceed the amount specified in appropriation Acts, or otherwise made available for obligation for such fiscal year.
The fees authorized by this section shall be available—
for fiscal year 2023, to defray the costs of the process for the review of biosimilar biological product applications (including such costs for an additional number of full-time equivalent positions in the Department* of Health and Human Services to be engaged in such process), only if the Secretary allocates for such purpose an amount for such fiscal year (excluding amounts from fees collected under this section) no less than $20,000,000, multiplied by the adjustment factor applicable to such fiscal year; and
for fiscal year 2024 and each subsequent fiscal year, to defray the costs of the process for the review of biosimilar biological product applications (including such costs for an additional number of full-time equivalent positions in the Department of Health and Human Services to be engaged in such process), only if the sum of the amounts allocated by the Secretary for such costs, excluding costs paid from fees collected under this section, plus other costs for the maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, and other necessary materials and supplies in connection with the process for the review of biosimilar biological product applications, is no less than $20,000,000, multiplied by the adjustment factor applicable to the fiscal year involved.
Beginning on October 1, 2023, the authorities under section 379j–51(9)(C) of this title shall include only leasing and necessary scientific equipment.
The Secretary shall be considered to have met the requirements of subparagraph (B)(i) in any fiscal year if the costs allocated as described in subclause (I) or (II) of such subparagraph, as applicable, are not more than 15 percent below the level specified in such subparagraph.
Payment of fees authorized under this section for a fiscal year, prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.
For each of fiscal years 2023 through 2027, there is authorized to be appropriated for fees under this section an amount equivalent to the total amount of fees assessed for such fiscal year under this section.
In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31.
To qualify for consideration for a waiver under subsection (d), or for the return of any fee paid under this section, including if the fee is claimed to have been paid in error, a person shall submit to the Secretary a written request justifying such waiver or return and, except as otherwise specified in this section, such written request shall be submitted to the Secretary not later than 180 days after such fee is due. A request submitted under this paragraph shall include any legal authorities under which the request is made.
This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employers, and advisory committees not engaged in the process of the review of biosimilar biological product applications, be reduced to offset the number of officers, employees, and advisory committees so engaged.
Source credit: (June 25, 1938, ch. 675, § 744H, as added Pub. L. 112–144, title IV, § 402, July 9, 2012, 126 Stat. 1029; amended Pub. L. 114–255, div. A, title III, § 3101(a)(2)(V), Dec. 13, 2016, 130 Stat. 1155; Pub. L. 115–52, title IV, § 403, title IX, § 905(b)(4), Aug. 18, 2017, 131 Stat. 1028, 1090; Pub. L. 116–136, div. A, title III, § 3856(b)(1), Mar. 27, 2020, 134 Stat. 458; Pub. L. 117–180, div. F, title IV, § 4003, Sept. 30, 2022, 136 Stat. 2160; Pub. L. 117–328, div. FF, title III, § 3625(b), Dec. 29, 2022, 136 Stat. 5880.)
- 1938Enacted · Pub. L. 112-144 · 126 Stat. 1029
- 2016Amended · Pub. L. 114-255 · 130 Stat. 1155
- 2017Amended · Pub. L. 115-52 · 131 Stat. 1028, 1090
- 2020Amended · Pub. L. 116-136 · 134 Stat. 458
- 2022Amended · Pub. L. 117-180 · 136 Stat. 2160
- 2022Amended · Pub. L. 117-328 · 136 Stat. 5880
A history note hasn’t been published yet. The record shows enactment by Pub. L. 112-144 on 1938-06-25.
all 0 arguments · sorted by: best
no arguments yet — make the first case